Disrupting the Immunosuppressive Myeloid Compartment in Solid Tumors
Manan Patel1, Kevin Van der Jeught2, Jashodeep Datta3
1Department of Surgery, University of Miami Miller School of Medicine, Miami, FL, USA.
Surgical Oncology Clinics of North America
|March 28, 2026
Summary
Myeloid cells drive cancer immune evasion and resistance to immunotherapy. Targeting myeloid cell recruitment, checkpoints, metabolism, and signaling offers a promising strategy for multimodal cancer treatment.
Area of Science:
- Oncology
- Immunology
- Cancer Research
Background:
- Immunotherapy has advanced cancer treatment, but solid tumors often resist T-cell-based strategies.
- Myeloid cells are increasingly recognized as key players in immune evasion, therapeutic resistance, and cancer progression.
Purpose of the Study:
- To review the biological mechanisms of myeloid-driven immunosuppression in cancer.
- To highlight translational strategies for targeting myeloid cells in cancer immunotherapy.
Main Methods:
- Literature review of myeloid cell biology in cancer.
- Analysis of current and emerging therapeutic strategies targeting myeloid cells.
Main Results:
- Myeloid cells contribute significantly to the immunosuppressive tumor microenvironment.
- Targeting myeloid cell recruitment, checkpoints, metabolic pathways, and signaling can overcome resistance.
Conclusions:
- Modulating myeloid cell function is crucial for enhancing cancer immunotherapy efficacy.
- Integrating myeloid-directed therapies with existing approaches holds significant therapeutic promise for solid tumors.
Keywords:
Dendritic cellsImmunotherapyPolymorphonuclear myeloid-derived suppressor cellsTumor associated macrophages
